Related Experiment Videos
Time course of regression of left ventricular hypertrophy in treated hypertensive patients
Insights
Methyldopa, alone or combined with hydrochlorothiazide, effectively reduced left ventricular hypertrophy in hypertensive patients. Long-term use of hydrochlorothiazide alone did not show similar regression of cardiac changes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension is a significant risk factor for left ventricular hypertrophy (LVH).
- LVH is associated with increased cardiovascular morbidity and mortality.
- Understanding the impact of antihypertensive medications on LVH regression is crucial for patient management.
Purpose of the Study:
- To investigate the effects of methyldopa, hydrochlorothiazide, and their combination on left ventricular hypertrophy in hypertensive patients.
- To determine the time course of regression of left ventricular hypertrophy following blood pressure control.
Main Methods:
- Prospective study involving 32 hypertensive patients with echocardiographic evidence of LVH.
- Treatment groups: methyldopa, hydrochlorothiazide, or combination therapy.
- Echocardiograms and electrocardiograms performed at baseline, during blood pressure control, and at 1, 3, 6, 12, and 18 months post-control.
Main Results:
- Significant reduction in left ventricular posterior wall thickness observed with methyldopa alone (p<0.01) and combination therapy (p<0.01), evident within one month.
- No significant reduction in LVH with hydrochlorothiazide alone (p=0.34).
- Ventricular septal thickness decreased with combination therapy (p=0.03) but increased with hydrochlorothiazide alone (p<0.01) over 18 months.
Conclusions:
- Regression of left ventricular hypertrophy can be detected as early as one month with methyldopa or combination therapy.
- Long-term hypertension control with hydrochlorothiazide alone was not associated with LVH regression.
- Suggests differential long-term effects of diuretics and sympatholytic drugs on left ventricular anatomy, potentially related to sympathetic nervous system modulation.
Abstract:
In a prospective study, 32 hypertensive patients with echocardiographic evidence of left ventricular hypertrophy were treated with methyldopa, hydrochlorothiazide, or methyldopa and hydrochlorothiazide combined. Echocardiograms and electrocardiograms were obtained in each of the 32 patients before treatment, at the point of initial blood pressure control, and then one, three, and six months thereafter; in 27 patients these studies were also obtained after 12 and 18 months. Left ventricular end-diastolic posterior wall thickness decreased in seven patients whose blood pressure was controlled with methyldopa alone (p less than 0.01) and in 17 patients whose blood pressure was controlled with methyldopa and hydrochlorothiazide combined (p less than 0.01); in both groups, the reduction in left ventricular posterior wall thickness at end-diastole was apparent one month after blood pressure control was established (p less than 0.05). In contrast, no significant reduction in left ventricular posterior wall thickness at end-diastole was observed in eight patients who had equivalent control of blood pressure with hydrochlorothiazide alone (p = 0.34). During the 18-month follow-up period, ventricular septal thickness at end-diastole decreased in the group treated with methyldopa and hydrochlorothiazide combined (p = 0.03); whereas, ventricular septal thickness at end-diastole appeared to increase in the group treated with hydrochlorothiazide alone (p less than 0.01). These results suggest that evidence of regression of left ventricular hypertrophy may be detected as early as one month after blood pressure is controlled with methyldopa or methyldopa and hydrochlorothiazide combined; whereas, long-term control of hypertension with hydrochlorothiazide alone was not associated with evidence of regression of left ventricular hypertrophy. Although the patient number are small, these data suggest that there are differences in the long-term effects of diuretics and sympatholytic drugs on left ventricular anatomy, which may, in part, relate to divergent effects on the sympathetic nervous system.